Form 4: Leap Therapeutics Chief Medical Officer Receives Stock Options

Cynthia Sirard, Chief Medical Officer of Leap Therapeutics, was granted stock options for 85,000 shares on October 2, 2024, according to a Form 4 filing.

Summary

• Cynthia Sirard, the Chief Medical Officer of Leap Therapeutics, Inc., received an employee stock option on October 2, 2024.
• The option grants her the right to buy 85,000 shares of Leap Therapeutics' common stock at an exercise price of $2.45 per share.
• The options vest in 36 equal monthly installments, starting one month after the grant date, contingent upon her continued employment with the company.
• The options expire on October 2, 2034.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. It reflects standard executive compensation practice, aligning management with shareholder interests. The vesting schedule promotes long-term commitment.

Positives

• The grant of stock options aligns the Chief Medical Officer's interests with those of the shareholders, incentivizing her to contribute to the company's success.
• The vesting schedule encourages long-term commitment from the executive.

Future Outlook

The vesting of the options is contingent upon continued employment, suggesting an expectation of continued service from the Chief Medical Officer.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align management's interests with those of shareholders.

Comparison to Industry Standards

• Stock option grants are a standard component of compensation packages for executives in publicly traded biotechnology companies.
• The size of the grant (85,000 shares) would need to be compared to grants made to similarly positioned executives at peer companies to determine if it is above, below, or in line with industry norms.
• Companies like Amgen, Gilead, and Biogen often use stock options as part of their executive compensation packages.

Stakeholder Impact

• Shareholders may view the option grant positively as it incentivizes the Chief Medical Officer to drive company success.
• Employees may see this as a positive sign of investment in leadership.

Key Dates